GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
GH Research PLC - Ordinary Shares (GHRS)
Company Research
Source: GlobeNewswire
Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry New peer-reviewed article in forthcoming issue of Psychopharmacology Bulletin demonstrates that GH001 efficacy is independent of prior antidepressant treatment failures DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced two peer-reviewed publications from its Phase 2b clinical program of GH001 in treatment-resistant depression (TRD): the primary trial results in JAMA Psychiatry, and a new analysis demonstrating that efficacy is independent of the number of prior lifetime treatment failures in a forthcoming issue of Psychopharmacology Bulletin. JAMA Psychiatry Publication The peer-reviewed article, titled “GH001 vs Placebo in Patients with Treatment-Resistant Depression” has been published today in JAMA Psychia
Show less
Read more
Impact Snapshot
Event Time:
GHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GHRS alerts
High impacting GH Research PLC - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GHRS
News
- What Does GH Research PLC (GHRS)'s Clinical Progress Updates Say? [Yahoo! Finance]Yahoo! Finance
- GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3 [Seeking Alpha]Seeking Alpha
- GH Research (GHRS) was given a new $34.00 price target by Guggenheim.MarketBeat
- GH Research (GHRS) had its price target raised by Citizens Jmp from $39.00 to $42.00. They now have a "market outperform" rating on the stock.MarketBeat
- GH Research (GHRS) had its price target raised by Needham & Company LLC from $31.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
GHRS
Earnings
- 3/5/26 - Miss
GHRS
Sec Filings
- 3/25/26 - Form 6-K
- 3/16/26 - Form 6-K
- 3/5/26 - Form S-8
- GHRS's page on the SEC website